Andrew Cooper
Stock Analyst at Raymond James
(2.43)
# 2,401
Out of 4,893 analysts
140
Total ratings
45.16%
Success rate
-0.79%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HAE Haemonetics | Reiterates: Strong Buy | $115 → $105 | $79.14 | +32.68% | 9 | May 9, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $5.52 | +81.32% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $19.70 | +26.94% | 2 | May 5, 2025 | |
| HOLX Hologic | Reiterates: Outperform | $90 → $71 | $66.73 | +6.40% | 12 | May 2, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $145 → $120 | $102.75 | +16.79% | 8 | Apr 29, 2025 | |
| ITGR Integer Holdings | Maintains: Outperform | $145 → $150 | $122.55 | +22.40% | 2 | Apr 25, 2025 | |
| UFPT UFP Technologies | Initiates: Market Perform | n/a | $255.34 | - | 1 | Mar 28, 2025 | |
| GH Guardant Health | Reiterates: Outperform | $39 → $59 | $51.04 | +15.60% | 3 | Feb 21, 2025 | |
| AVTR Avantor | Reiterates: Outperform | $26 → $24 | $13.88 | +72.97% | 14 | Feb 10, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $650 → $667 | $431.39 | +54.62% | 6 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $206.46 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $54.77 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $20.65 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $162.43 | -47.67% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $32.12 | +136.65% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $3.58 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $34.54 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $7.58 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $27.31 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.04 | - | 5 | Sep 22, 2021 |
Haemonetics
May 9, 2025
Reiterates: Strong Buy
Price Target: $115 → $105
Current: $79.14
Upside: +32.68%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $5.52
Upside: +81.32%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $19.70
Upside: +26.94%
Hologic
May 2, 2025
Reiterates: Outperform
Price Target: $90 → $71
Current: $66.73
Upside: +6.40%
Revvity
Apr 29, 2025
Reiterates: Outperform
Price Target: $145 → $120
Current: $102.75
Upside: +16.79%
Integer Holdings
Apr 25, 2025
Maintains: Outperform
Price Target: $145 → $150
Current: $122.55
Upside: +22.40%
UFP Technologies
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $255.34
Upside: -
Guardant Health
Feb 21, 2025
Reiterates: Outperform
Price Target: $39 → $59
Current: $51.04
Upside: +15.60%
Avantor
Feb 10, 2025
Reiterates: Outperform
Price Target: $26 → $24
Current: $13.88
Upside: +72.97%
Thermo Fisher Scientific
Feb 3, 2025
Reiterates: Outperform
Price Target: $650 → $667
Current: $431.39
Upside: +54.62%
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $206.46
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $54.77
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $20.65
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $162.43
Upside: -47.67%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $32.12
Upside: +136.65%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $3.58
Upside: -
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $34.54
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $7.58
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $27.31
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.04
Upside: -